HALOZYME THERAPEUTICS, INC. (HALO)
Biological Products, (No Diagnostic Substances) · Healthcare · $8.3B
Intrinsic Value (Consensus)
$48.33
Current Price
$69.64
Margin of Safety
-30.6%
30.6% Above Intrinsic Value
Value: $48
Price: $70
Valuation Model Estimates
Current Price: $69.64
DCF (Discounted Cash Flow)
$68.95
Graham Number
$4.87
Earnings Power Value
$24.85
Relative Value (P/E)
$51.20
Dividend Discount Model
Not applicable
—
Consensus Value
$48.33
Model Assumptions
Discount Rate
10.3%
Growth Rate
2.0%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
C
60
Profitability
25/25
Strength
12/25
Valuation
7/25
Growth
16/25
Financial Health Signals
Very high debt — Debt/Equity ratio is 4389% (above 200% is risky)
Strong profitability — ROE of 649% (above 20% is excellent)
Key Financials
- EPS (TTM)
- $2.56
- EPS (Forward)
- $2.61
- Book Value
- $0.41
- P/E Ratio
- 20.0
- Forward P/E
- 19.6
- PEG Ratio
- —
- ROE
- 649.2%
- Debt/Equity
- 4389%
- Revenue Growth
- 37.6%
- Earnings Growth
- 2.0%
- Dividend Yield
- N/A
- Beta
- 1.00
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-16
Source: Yahoo Finance